ACOR Financial Facts

Total net revenues: 97.13M
Loss before taxes: 10.72M
See Full Income Statement

Total liabilities and stockholders' equity: 943.32M
Current portion of convertible notes payable: 1.14M
See Full Balance Sheet

Acorda Therapeutics, Inc. (ACOR) Earnings

  |   Expand Research on ACOR
Next EPS Date 10/31/14 *Est. EPS Growth Rate +68.0% *Last Qtr.
Average EPS % Beat Rate +142.0% Revenue Growth Rate +11.6% *Last Qtr.
Average % Move 1-Wk after EPS +2.7% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
7/31/14 Q214 $0.42$0.15 +$0.27$97.13M$91.4M N/A Details
11/4/11 Q311 $0.40$0.73 -$0.33$93.03M$90.78M N/A Details
10/31/13 Q313 $0.36$0.13 +$0.23$84.92M$90.01M N/A Details
2/13/14 Q413 $0.32$0.18 +$0.14$92.59M$89.96M N/A Details
8/1/13 Q213 $0.25$0.09 +$0.16$87.05M$82.57M N/A Details
5/6/14 Q114 $0.21$0.09 +$0.12$80.52M$81.3M N/A Details
5/2/13 Q113 $0.09$0.13 -$0.04$62.3M$80.71M N/A Details
2/13/13 Q412 $0.24$0.15 +$0.09$81.47M$78.9M N/A Details